KTTA

Pasithea Therapeutics Corp. KTTA

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.5M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/KTTA

Earnings Per Share

13fpro.ai/company/KTTA

Loading ratio trend…

KTTA insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Pasithea Therapeutics Corp. (KTTA): stock profile, AI score and financials

Pasithea Therapeutics Corp. (KTTA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. KTTA is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.5m in revenue and is scored on the micro-cap board instead. KTTA trades on the Nasdaq exchange and files with the SEC under CIK 1841330. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KTTA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Pasithea Therapeutics Corp. directly from SEC EDGAR.

SEC EDGAR: CIK 1841330 →